Literature DB >> 23877259

Ca2+/calmodulin-dependent protein kinase II and protein kinase A differentially regulate sarcoplasmic reticulum Ca2+ leak in human cardiac pathology.

Thomas H Fischer1, Jonas Herting, Theodor Tirilomis, André Renner, Stefan Neef, Karl Toischer, David Ellenberger, Anna Förster, Jan D Schmitto, Jan Gummert, Friedrich A Schöndube, Gerd Hasenfuss, Lars S Maier, Samuel Sossalla.   

Abstract

BACKGROUND: Sarcoplasmic reticulum (SR) Ca(2+) leak through ryanodine receptor type 2 (RyR2) dysfunction is of major pathophysiological relevance in human heart failure (HF); however, mechanisms underlying progressive RyR2 dysregulation from cardiac hypertrophy to HF are still controversial. METHODS AND
RESULTS: We investigated healthy control myocardium (n=5) and myocardium from patients with compensated hypertrophy (n=25) and HF (n=32). In hypertrophy, Ca(2+)/calmodulin-dependent protein kinase II (CaMKII) and protein kinase A (PKA) both phosphorylated RyR2 at levels that were not different from healthy myocardium. Accordingly, inhibitors of these kinases reduced the SR Ca(2+) leak. In HF, however, the SR Ca(2+) leak was nearly doubled compared with hypertrophy, which led to reduced systolic Ca(2+) transients, a depletion of SR Ca(2+) storage and elevated diastolic Ca(2+) levels. This was accompanied by a significantly increased CaMKII-dependent phosphorylation of RyR2. In contrast, PKA-dependent RyR2 phosphorylation was not increased in HF and was independent of previous β-blocker treatment. In HF, CaMKII inhibition but not inhibition of PKA yielded a reduction of the SR Ca(2+) leak. Moreover, PKA inhibition further reduced SR Ca(2+) load and systolic Ca(2+) transients.
CONCLUSIONS: In human hypertrophy, both CaMKII and PKA functionally regulate RyR2 and may induce SR Ca(2+) leak. In the transition from hypertrophy to HF, the diastolic Ca(2+) leak increases and disturbed Ca(2+) cycling occurs. This is associated with an increase in CaMKII- but not PKA-dependent RyR2 phosphorylation. CaMKII inhibition may thus reflect a promising therapeutic target for the treatment of arrhythmias and contractile dysfunction.

Entities:  

Keywords:  calcium–calmodulin-dependent protein kinase type 2; heart failure; hypertrophy; protein kinases; sarcoplasmic reticulum

Mesh:

Substances:

Year:  2013        PMID: 23877259     DOI: 10.1161/CIRCULATIONAHA.113.001746

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  61 in total

Review 1.  Transient outward potassium channel: a heart failure mediator.

Authors:  Qianwen He; Ying Feng; Yanggan Wang
Journal:  Heart Fail Rev       Date:  2015-05       Impact factor: 4.214

2.  Stage-dependent benefits and risks of pimobendan in mice with genetic dilated cardiomyopathy and progressive heart failure.

Authors:  Miki Nonaka; Sachio Morimoto; Takashi Murayama; Nagomi Kurebayashi; Lei Li; Yuan-Yuan Wang; Masaki Arioka; Tatsuya Yoshihara; Fumi Takahashi-Yanaga; Toshiyuki Sasaguri
Journal:  Br J Pharmacol       Date:  2015-03-17       Impact factor: 8.739

3.  Calmodulin inhibition of human RyR2 channels requires phosphorylation of RyR2-S2808 or RyR2-S2814.

Authors:  Kafa Walweel; Nieves Gomez-Hurtado; Robyn T Rebbeck; Ye Wint Oo; Nicole A Beard; Peter Molenaar; Cris Dos Remedios; Dirk F van Helden; Razvan L Cornea; Björn C Knollmann; Derek R Laver
Journal:  J Mol Cell Cardiol       Date:  2019-03-27       Impact factor: 5.000

4.  Genetic ablation of ryanodine receptor 2 phosphorylation at Ser-2808 aggravates Ca(2+)-dependent cardiomyopathy by exacerbating diastolic Ca2+ release.

Authors:  Bin Liu; Hsiang-Ting Ho; Florencia Velez-Cortes; Qing Lou; Carmen R Valdivia; Bjorn C Knollmann; Hector H Valdivia; Sandor Gyorke
Journal:  J Physiol       Date:  2014-01-20       Impact factor: 5.182

5.  Multisite phosphorylation of the cardiac ryanodine receptor: a random or coordinated event?

Authors:  Jana Gaburjakova; Eva Krejciova; Marta Gaburjakova
Journal:  Pflugers Arch       Date:  2020-10-19       Impact factor: 3.657

6.  A proteolytic fragment of histone deacetylase 4 protects the heart from failure by regulating the hexosamine biosynthetic pathway.

Authors:  Lorenz H Lehmann; Zegeye H Jebessa; Michael M Kreusser; Axel Horsch; Tao He; Mariya Kronlage; Matthias Dewenter; Viviana Sramek; Ulrike Oehl; Jutta Krebs-Haupenthal; Albert H von der Lieth; Andrea Schmidt; Qiang Sun; Julia Ritterhoff; Daniel Finke; Mirko Völkers; Andreas Jungmann; Sven W Sauer; Christian Thiel; Alexander Nickel; Michael Kohlhaas; Michaela Schäfer; Carsten Sticht; Christoph Maack; Norbert Gretz; Michael Wagner; Ali El-Armouche; Lars S Maier; Juan E Camacho Londoño; Benjamin Meder; Marc Freichel; Hermann-Josef Gröne; Patrick Most; Oliver J Müller; Stephan Herzig; Eileen E M Furlong; Hugo A Katus; Johannes Backs
Journal:  Nat Med       Date:  2017-12-11       Impact factor: 53.440

7.  Alamandine enhances cardiomyocyte contractility in hypertensive rats through a nitric oxide-dependent activation of CaMKII.

Authors:  Itamar Couto Guedes Jesus; Thássio Ricardo Ribeiro Mesquita; André Luís Lima Monteiro; Amanda Borges Parreira; Anderson Kenedy Santos; Elizeu Lucas Xavier Coelho; Mário Morais Silva; Lucas A C Souza; Maria José Campagnole-Santos; Robson Souza Santos; Silvia Guatimosim
Journal:  Am J Physiol Cell Physiol       Date:  2020-01-08       Impact factor: 4.249

8.  Ranolazine prevents pressure overload-induced cardiac hypertrophy and heart failure by restoring aberrant Na+ and Ca2+ handling.

Authors:  Jiali Nie; Quanlu Duan; Mengying He; Xianqing Li; Bei Wang; Chi Zhou; Lujin Wu; Zheng Wen; Chen Chen; Dao Wu Wang; Katherina M Alsina; Xander H T Wehrens; Dao Wen Wang; Li Ni
Journal:  J Cell Physiol       Date:  2018-11-29       Impact factor: 6.384

Review 9.  Heart failure-specific changes in protein kinase signalling.

Authors:  Kristina Lorenz; Konstantina Stathopoulou; Evelyn Schmid; Petra Eder; Friederike Cuello
Journal:  Pflugers Arch       Date:  2014-02-08       Impact factor: 3.657

10.  Role of RyR2 phosphorylation in heart failure and arrhythmias: Controversies around ryanodine receptor phosphorylation in cardiac disease.

Authors:  Dobromir Dobrev; Xander H T Wehrens
Journal:  Circ Res       Date:  2014-04-11       Impact factor: 17.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.